CTLA4 and neoplasm: In this study, we report that the concurrent neutralisation of RANKL and PD‐1 by a BsAb consistently demonstrated superior anti‐tumor or anti‐metastatic control to monotherapies, even in settings in which anti‐PD‐1 or anti‐CTLA‐4 treatment alone evoked minimal anti‐tumor activities.